Application of oat inhibitor and oncolytic virus in the preparation of antitumor drugs

An oncolytic virus and inhibitor technology, which is applied to the application field of OAT inhibitors and oncolytic viruses in the preparation of anti-tumor drugs, can solve the problems of different M1 virus sensitivities, unsatisfactory oncolytic effects, etc., and achieves improved treatment. Effectiveness, increased antitumor effect, enhanced inhibitory effect

Active Publication Date: 2021-09-28
SUN YAT SEN UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, different tumors have different sensitivities to M1 virus, and for some tumors, when M1 virus is used alone, the oncolytic effect is not ideal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oat inhibitor and oncolytic virus in the preparation of antitumor drugs
  • Application of oat inhibitor and oncolytic virus in the preparation of antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Combined treatment of Dimesna and M1 virus significantly reduces the survival rate of human hepatocellular carcinoma line Hep3B

[0032] Material:

[0033] Human hepatocellular carcinoma Hep3B (purchased from ATCC), M1 virus (preservation number CCTCC V201423), high-glucose DMEM medium (purchased from Corning), multi-functional microplate reader.

[0034] In this embodiment, the OAT inhibitor is Dimesna, whose structural formula is shown in Formula 1:

[0035]

[0036] Formula 1: Dimesna.

[0037] method:

[0038] a) Inoculation of cells, administration treatment: select logarithmic growth phase cells, DMEM complete culture medium (containing 10% fetal bovine serum, 1% double antibody) to make cell suspension, inoculate with the density of 4 × 103 cells in each hole 96-well culture plate. After 12 hours, the cells were completely adhered to the wall. The experiments were divided into control group, Dimesna single use group, M1 infection group and Dimesn...

Embodiment 2

[0044] A pharmaceutical composition for treating tumors, comprising an organic anion transporter subfamily inhibitor and an oncolytic virus.

[0045] It can also be a medicine set for treating tumors, which comprises an OAT inhibitor or a derivative thereof or a combination thereof, and an oncolytic virus. The difference between the medicine set and the composition is that the OAT inhibitor is different from the dosage form of the oncolytic virus, but is packaged independently (for example: in a pill, or capsule, or tablet or ampoule, containing the OAT inhibitor; another pill, or capsules, or tablets, or ampoules, containing oncolytic viruses).

[0046] Oncolytic viruses, OAT inhibitors, and combinations of oncolytic viruses and OAT inhibitors may also contain one or more adjuvants. The adjuvant refers to a component in the composition of the medicine that can assist the curative effect of the medicine. The medicine set can also contain an independently packaged OAT inhibit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses for the first time that OAT inhibitors, especially Dimesna, can increase the anti-tumor effect of oncolytic viruses, so as to improve the therapeutic effectiveness of oncolytic viruses as anti-tumor drugs. Cytological experiments have proved that the combined application of M1 virus and Dimesna can significantly cause morphological changes in tumor cells, thereby significantly enhancing the inhibitory effect on tumor cells.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and more specifically relates to the application of OAT inhibitors and oncolytic viruses in the preparation of antitumor drugs. Background technique [0002] Oncolytic virus is a kind of replication-competent virus that targets and infects and kills tumor cells without damaging normal cells. Oncolytic virus therapy (oncolytic virotherapy) is an innovative tumor-targeted treatment strategy, which uses natural or genetically engineered viruses to selectively infect tumor cells and replicate in tumor cells to achieve targeted dissolution, The effect of killing tumor cells, but no damage to normal cells. [0003] Oncolytic virus M1 is a Getta-like virus of the Togaviridae alphavirus genus, isolated from mosquitoes of the genus Culex in Hainan Island, China. For example, Chinese invention patent application CN104814984A discloses that oncolytic virus M1 can selectively cause tumor cell death wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/185A61K35/768A61K35/766A61K35/761A61K35/763A61P35/00
CPCA61K31/185A61K35/761A61K35/763A61K35/766A61K35/768A61K45/00A61P35/00A61K2300/00
Inventor 林园梁剑开蔡静苏兴文
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap